Takeda Pharmaceutical Non-GAAP EPS of ¥308.00, revenue of ¥2407B; upgrades FY 2026 outlook

• Takeda Pharmaceutical press release (TAK): 1H Non-GAAP EPS of ¥308.00.
• Revenue of ¥2,407B (+8.4% Y/Y).
• Adjusted Free Cash Flow was JPY 325.7 billion.
• FY2026 full-year outlook upgraded to reflect FX benefit.

• FY2026 Full-year Forecast and Guidance
  Takeda raised its FY2026 outlook mainly due to FX benefit.
  (Billion yen, except percentages and per share amounts)
  Item	FY2026 ORIGINAL MANAGEMENT GUIDANCE AT CER (MAY 2026)	FY2026 REVISED MANAGEMENT GUIDANCE AT CER (OCT 2026)
  Core Revenue	Low-single digit % decline	Low-single digit % decline
  Core Operating Profit	5% to 8% decline	Mid-single digit % decline
  Core EPS (Yen)	Mid-teens % decline	Low-teens % decline

  Item	FY2026 ORIGINAL FORECAST (MAY 2026)	FY2026 REVISED FORECAST (OCT 2026)
  Revenue	4,640.0	4,700.0
  Core Revenue (Non-IFRS)	4,640.0	4,700.0
  Operating Profit	420.0	453.0
  Core Operating Profit (Non-IFRS)	1,160.0	1,190.0
  Net Profit	166.0	209.0
  EPS (Yen)	104	131
  Core EPS (Yen) (Non-IFRS)	472	482
  Adjusted Free Cash Flow (Non-IFRS)	650.0 – 750.0	700.0-800.0
  Annual dividend per share (Yen)	204	204

Recommended For You

Register for free to keep reading.

Create a free account to get unlimited breaking news and alerts when your stocks move.